According to filings with the U.S. Securities and Exchange Commission, Xsphera Biosciences is raising $19,899,952.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Stephen Remondi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Xsphera Biosciences
About Xsphera Biosciences envisions a world where failure is no longer the most likely outcome in oncology clinical trials. Our ex vivo platform, invented at the Dana-Farber Cancer Institute, is a powerful integration of biology and cloud computing that accelerates drug development. Xsphera uniquely enables the study of single-variable testing, which is not possible with in vivo studies. Human Tissue Predicts Human Response Drug testing is dominated by in vivo tests of engineered mice – which are notoriously poor predictors of drug performance. Xsphera believes human tissue is the best predictor of human response. High quality, human tissue samples are sourced from our clinical network. Xsphera then captures the entirety of each patients tumor microenvironment in microfluidic devices. Each channel is treated with different therapeutics and multiple endpoints are measured including immune stimulation and tumor cell death. Unlock the Mysteries of Drug Mechanisms Xsphera unlocks the mysteries of drug mechanisms with our cloud platform that integrates complex multi-omic response data for each patient into a unified, intelligent interface. This accelerates scientific understanding of why patients respond to or resist therapies. Improved understanding leads to reduced clinical failure rates. With Xsphera, novel therapeutics move into the clinic with confidence. Turn Overwhelming Data into Rapid Understanding Drug developers are confronted with vast amounts of overwhelming and scattered data as they attempt to extract scientific understanding from study analytics. As a result, unquantifiable volumes of valuable study data sit un-analyzed on hard drives. With Xsphera, no data is left behind. Our cloud-based platform ingests and integrates tissue, patient and results data into a single unified source. AI-driven algorithms automate deep analysis and put previously unknowable insights within reach.

To learn more about Xsphera Biosciences, visit http://www.xspherabio.com/

Contact:
Stephen Remondi, Chief Executive Officer
617-832-3030

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.